Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this extension study is to assess the long-term safety and tolerability of
omalizumab as an add-on therapy in Japanese pediatric patients (6 to 15 years of age) with
inadequately controlled allergic asthma despite current recommended treatment by providing
continued treatment with omalizumab to patients who have previously completed the core study.